Pembrolizumab Efficacy in Treatment of Carcinoma of the Head and Neck Squamous Cell
- DOI
- 10.2991/ahsr.k.220206.019How to use a DOI?
- Keywords
- Cancer Treatment; Head and Neck Squamous Cell Carcinoma; Immunotherapy; Pembrolizumab
- Abstract
Immunotherapy acts by a system of immune modulation to destruct cells of cancer. Squamous cell carcinoma of the head and neck (HNSCC), this modality can be administered alone or combined with other therapies. Currently, immunotherapy with chemotherapy has shown better effectiveness as first-line systemic therapy. Immunotherapy drugs are divided into T-cell treatment and checkpoint inhibitors divided into chimeric antigen receptor (CAR). Pembrolizumab is categorized as checkpoint inhibitors and is currently being researched for its role in HNSCCs management. Pembrolizumab can be used the first or second-line for recurrent or metastatic (R/M) HNSCC. In addition, the side effects of Pembrolizumab are more tolerable than standard chemotherapy regimens.
- Copyright
- © 2022 The Authors. Published by Atlantis Press International B.V.
- Open Access
- This is an open access article under the CC BY-NC license.
Cite this article
TY - CONF AU - Yussy Afriani Dewi AU - Ifiq Budiyan Nazar AU - Betty S. Hermono PY - 2022 DA - 2022/02/21 TI - Pembrolizumab Efficacy in Treatment of Carcinoma of the Head and Neck Squamous Cell BT - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021) PB - Atlantis Press SP - 93 EP - 96 SN - 2468-5739 UR - https://doi.org/10.2991/ahsr.k.220206.019 DO - 10.2991/ahsr.k.220206.019 ID - Dewi2022 ER -